SAN MATEO, Calif. – Pharmaceutical company Sanofi and Evidation Health have extended their partnership for three years to use patient-generated health data to develop innovative solutions and improve outcomes for disease management.
Sanofi will tap Evidation’s expertise in quantifying the impact of patient behaviors in real life on the eventual outcome of a course of treatment. The agreement builds upon Evidation Health and Sanofi’s prior work in translating patient-generated behavioral data to quantified clinical and economic outcomes.
“Consumers are sharing their digital footprint through wearables, sensors and apps, and we need to listen, so we can better help them navigate their day-to-day health journey,” said Christine Lemke, cofounder and president of Evidation Health, in a statement. “By partnering with Sanofi’s innovative team, we have an opportunity to better manage population health in the digital era by illuminating underlying health behaviors in a privacy-safe and patient-permissioned way.”
The Evidation technology platform enables life sciences companies to efficiently evaluate the impact of behaviors on health outcomes through linking real-life data from connected devices with medical and contextual data in virtual studies that leverage digital biomarkers across therapeutic areas.
“Working closely with Evidation and its distinctive analytics platform will help us better understand the factors that affect patient outcomes,” said Heather Bell, senior vice president and global head of digital and analytics at Sanofi. “We can then use those insights to support patients and health care professionals in managing disease and delivering the most value from our therapies.”